Muller P, Chowdhury K, Gordon C, Ehrenstein MR, Dore CJ. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan. Trials. 2020;21(1).
Sloan M, Harwood R, Sutton S, D'Cruz D, Howard P, Wincup C, et al, Gordon C. Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatol Adv Pract. 2020;4(1).
Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020;79(3):356-62.
Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, et al. Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatol Adv Pract. 2019;3(2):rkz021.
Tosounidou S, Gordon C. Medications in pregnancy and breastfeeding. Best Pract Res Clin Obstet Gynaecol. 2019.
Lim SS, Helmick CG, Bao G, Hootman J, Bayakly R, Gordon C, et al. Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus - Fulton and DeKalb Counties, Georgia, 2002-2016. MMWR Morb Mortal Wkly Rep. 2019;68(18):419-22.
Dall'Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE. Current challenges in the development of new treatments for lupus. Ann Rheum Dis. 2019;78(6):729-35.
Isenberg D, et al, Gordon C: A study of flare assessment in systemic lupus erythematosus (SLE) based on paper patients. Arthritis Care Res (Hoboken ) 2018;70:98-103.
GordonC, Amissah-Arthur M-B, Gayed M, Brown S, Bruce IN, D'Cruz D, Empson B, Griffiths B JayneD, KhamashtaM, LightstoneL, NortonP, NortonY, SchreiberK, IsenbergD. The British Society for Rheumatology guidelines for the management of systemic lupus erythematosus in adults: Executive summary. Rheumatology (Oxford) 2018;57(1):14-18
GordonC, Amissah-Arthur M-B, Gayed M, Brown S, Bruce IN, D'Cruz D, Empson B, Griffiths B JayneD, KhamashtaM, LightstoneL, NortonP, NortonY, SchreiberK, IsenbergD.The British Society for Rheumatology guidelines for the management of systemic lupus erythematosus in adults.Rheumatology (Oxford) 2018; 57(1):e1–e45
Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, Arthanari S, Cunningham J, Flanders L, Moore L, Crossley A, Purushotham N, Desai A, Piper M, Nisar M, Khamashta M, Williams D, Gordon C and Giles I; BSR and BHPR Standard, Guidelines and Audit Working Group (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford) 55: 1698-1702
Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, Arthanari S, Cunningham J, Flanders L, Moore L, Crossley A, Purushotham N, Desai A, Piper M, Nisar M, Khamashta M, Williams D, Gordon C and Giles I; BSR and BHPR Standard, Guidelines and Audit Working Group (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 55: 1693-1697
Gordon C, Wofsy D, Wax S, Li Y, Pena RC, Isenberg D. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis Rheumatol 2017; 69(1):122-30.
Clowse ME, et al., Gordon C. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Arthritis Rheumatol 2017; 69(2):362-75.
McElhone K, et al., Gordon C, Teh L-S. Sensitivity to Change (Responsiveness) and Minimal Important Differences of the LupusQoL in patients with SLE. Arthritis Care & Research 2016; 68:1505-1513.
Isenberg D, Gordon C, Licu D, Copt S, Rossi C and Wofsy D (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate to severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Annals Rheumatic Diseases 74(11):2006-15
Gordon C, et al.The substantial burden of SLE on the productivity & careers of patients: a European patient-driven online survey. Rheumatology (Oxford) 2013; 52:2292-2301
Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, Farewell V and Gordon C (2015) Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford) 54:836-43
Yee CS, Cresswell L, Farewell V, Rahman A, The LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D’Cruz D, Khamashta MA, Isenberg DA and Gordon C (2010) Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 49(9):1665-9
Yee CS, et al, Gordon C. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009; 48(6):691-695.
View all publications in research portal